Efficacy of Acupuncture on Chemotherapy-Induced Peripheral Neuropathy (CIPN) (NCT04651907) | Clinical Trial Compass
CompletedNot Applicable
Efficacy of Acupuncture on Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Taiwan69 participantsStarted 2021-02-18
Plain-language summary
The purpose of this study is to assess the neurological efficacy of acupuncture in patients with cancer who experienced peripheral neuropathy, which is induced by chemotherapy.
Who can participate
Age range
20 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. All adult cancer patients (Age≧20-year-old) who received chemotherapy regimens, including adjuvant and neoadjuvant therapy
. Stage I-III cancer patients
. Completed chemotherapy regimens more than3 months, including Taxanes (paclitaxel or docetaxel), platinum (cisplatin, oxaliplatin, carboplatin)
. Baseline von Frey Monofilament test (Target force at hand) ≧ 0.07gms
. Baseline von Frey Monofilament test (Target force at foot) ≧ 0.4gms
. Eastern Cooperative Oncology Group (ECOG) performance status ≦3
. Grading of peripheral sensory neuropathy in National Cancer Institute- common terminology criteria for adverse events,v5.0 (NCI-CTCAE5) ≧1
. Patients were restricted acupuncture treatment for one month before recruitment
Exclusion criteria
. Uncontrolled Diabetic Mellitus, HbA1c≧7% is inappropriate\[19\].
. Diabetic neuropathy diagnosed before receiving chemotherapy
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The change of FACT-Neurotoxicity subscale(NtxS)
Timeframe: It will be assessed before the first session, after the 12th session, the 20th session, and followed at the end of the 12th week.
. Neuropathy from any type of nerve compression (e.g., carpal/tarsal tunnel syndrome, radiculopathy, spinal stenosis, brachial plexopathy)
. Concomitant with duloxetine, or another analgesia, including Pregabalin, Venlafaxine, Minocycline, Topical gel, Oxycodone, Naloxone, Cannabinoids, and Angiotensin II type 2 receptor antagonist
. Severe hemorrhagic coagulopathy or bleeding tendency
. Unstable cardiovascular disease
. Severe skin lesions around the treatment sites The researchers will exclude any participants considered to be inappropriate for the study.